VGXI competitors

Key experiences in leading mergers and acquisitions, working with financial institutions and markets, driving exceptional growth in revenue and profit, developing organizations, managing organizational performance, and planning strategic growth. Specialties: Mergers and acquisitions, General Management, Marketing, Sales, Quality Systems.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Barry Quart, Pharm.D. has served as a director of Heron since 2012. Dr. Quart was appointed Chief Executive Officer of the Company in 2013 and President and Chief Executive Officer of the Company in February 2019. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through 2013 and as a director through its acquisition by AstraZeneca PLC in 2012. Previously, he was with Pfizer Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in 2015. Since 2015, Dr. Quart has served as a director of Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.

Executive Officer with over 20 years of transactional and operational experience in venture capital backed startups to mature fully integrated organizations in the biotechnology, medical device, and pharmaceutical industries. Completed strategic transactions & shareholder exits totaling |$530M, venture capital/royalty fundraising totaling |$70M, and public offerings (IPO and secondary) totaling |$200M. Established strategy as part of executive management teams, growing revenues to |$300M, hired and led senior (C-Level to VP level) leadership teams, and secured multiple FDA PMA, NDA, and 510(k) approvals. Functional leadership in and P&L responsibility for market development, international sales distribution, M&A/business development, R&D, regulatory & clinical affairs, manufacturing & logistics, patent & legal affairs, quality operations, facilities, finance, and information technology.Areas of expertise include: Organization Transformation, R&D, Strategic Planning, Integrating Acquisitions and Products, Business Development, Investor & Shareholder Relations, Board of Directors and KOL Engagement, Crisis Management & Restructuring, Product Development, FDA & Global Regulatory Approvals, Lean & Continuous Improvement, Financial Analysis, and P&L/Cost Management.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

Experienced Biopharma & Technology Founder, Executive & Board Member with a demonstrated history of working in the Life Sciences & Information Technology industries across continents.

Elizabeth A. Hutt is an Advisor at zPREDICTA and Chief Executive Officer at NUGEN TECHNOLOGIES INC.